Original language | English (US) |
---|---|
Pages (from-to) | 1202-1203 |
Number of pages | 2 |
Journal | Clinical and experimental rheumatology |
Volume | 41 |
Issue number | 5 |
DOIs | |
State | Published - May 2023 |
ASJC Scopus subject areas
- Rheumatology
- Immunology and Allergy
- Immunology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Clinical and experimental rheumatology, Vol. 41, No. 5, 05.2023, p. 1202-1203.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Low Omicron BA.4 and BA.5 neutralising activity and breakthrough COVID-19 following pre-exposure prophylaxis with Tixagevimab plus Cilgavimab in vaccinated patients with autoimmune disease
AU - Connolly, C. M.
AU - Karaba, A. H.
AU - Chiang, T. Po Yu
AU - Teles, M.
AU - Kim, J. D.
AU - Johnson, T. Scott
AU - Alejo, J. L.
AU - Segev, D. L.
AU - Christopher-Stine, L.
AU - Werbel, W. A.
AU - Paik, J. J.
N1 - Funding Information: his work was made possible by the generous support of the Ben-Dov and Trokhan Patterson families. This work was supported by the Jerome L. Greene Foundation Discovery Fund (C.M. Connolly, J.J. Paik) and grant number K23AR073927 (J.J. Paik) from National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), T32DK007713 (J.L. Alejo) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), K24AI144954 (D.L. Segev), U01AI138897-S04, K08AI156021 (A.H. Karaba), and K23AI157893 (W.A. Werbel) from National Institute of Allergy and Infectious Diseases (NIAID). The analyses described here are the responsibility of the authors alone and do not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organisations imply endorsement by the US Government. Funding Information: *Contributed equally as first authors. **Contributed equally as senior authors. 1Division of Rheumatology, 2Division of Infectious Diseases, Department of Medicine, 3Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD; 4Department of Surgery, NYU Grossman School of Medicine, New York, NY, USA. Please address correspondence to: Julie J. Paik, Division of Rheumatology, Johns Hopkins University, 5501 Hopkins Bayview Circle, Baltimore, MD 21224, USA. E-mail: jpaik1@jhmi.edu Funding: this work was made possible by the generous support of the Ben-Dov and Trokhan Patterson families. This work was supported by the Jerome L. Greene Foundation Discovery Fund (C.M. Connolly, J.J. Paik) and grant number K23AR073927 (J.J. Paik) from National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), T32DK007713 (J.L. Alejo) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), K24AI144954 (D.L. Segev), U01AI138897-S04, K08AI156021 (A.H. Karaba), and K23AI157893 (W.A. Werbel) from National Institute of Allergy and Infectious Diseases (NIAID). The analyses described here are the responsibility of the authors alone and do not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organisations imply endorsement by the US Government. Competing interests: D.L. Segev reports receiving honoraria from Sanofi (speaking), Novartis (speaking, consulting), Veloxis (consulting), Mallinckrodt (consulting), Jazz Pharmaceuticals (consulting), CSL Behring (consulting), Thermo Fisher Scientific (consulting), Caredx (speaking, consulting), Transmedics (consulting), Kamada (consulting), MediGO (consulting), Regeneron (consulting), AstraZeneca (speaking, consulting), Novavax (advisory board), Takeda (consulting), and Bridge to Life (speaking). L. Christopher-Stine reports consultant fees from Janssen, Boehringer-Ingelheim, Mallinckrodt, EMD-Serono, Allogene, and ArgenX. A.H. Karaba reports consultant fees from Roche. W.A. Werbel reports speaking fees from Astra-Zeneca and honoraria from Novavax (advisory board). J.J. Paik reports consultant fees from Alexion, ArgenX, EMD-Serono, Guidepoint, Kezar, and Pfizer. The other authors have declared no competing interests. © Copyright CliniCal and ExpErimEntal rhEumatology 2023.
PY - 2023/5
Y1 - 2023/5
UR - http://www.scopus.com/inward/record.url?scp=85159545677&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85159545677&partnerID=8YFLogxK
U2 - 10.55563/clinexprheumatol/pfli7o
DO - 10.55563/clinexprheumatol/pfli7o
M3 - Letter
C2 - 36826787
AN - SCOPUS:85159545677
SN - 0392-856X
VL - 41
SP - 1202
EP - 1203
JO - Clinical and experimental rheumatology
JF - Clinical and experimental rheumatology
IS - 5
ER -